Royal Bank of Canada
PYXS icon

Royal Bank of Canada’s Pyxis Oncology PYXS Stock Holding History

Royal Bank of Canada’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9K Sell
5,839
-49,712
-89% -$74.9K ﹤0.01% 6220
2025
Q4 		$64K Sell
55,551
-22,429
-29% -$79.1K ﹤0.01% 5426
2025
Q3 		$173K Sell
77,980
-8,385
-10% -$12.1K ﹤0.01% 5175
2025
Q2 		$95K Sell
86,365
-10,294
-11% -$11.6K ﹤0.01% 5636
2025
Q1 		$95K Buy
96,659
+69,006
+250% +$92.1K ﹤0.01% 5256
2024
Q4 		$44K Sell
27,653
-7,673
-22% -$22.1K ﹤0.01% 5757
2024
Q3 		$130K Buy
35,326
+5,133
+17% +$18K ﹤0.01% 5160
2024
Q2 		$100K Buy
30,193
+4,593
+18% +$19.3K ﹤0.01% 5267
2024
Q1 		$109K Buy
25,600
+24,647
+2,586% +$104K ﹤0.01% 5150
2023
Q4 		$2K Sell
953
-2,320
-71% -$3.97K ﹤0.01% 6832
2023
Q3 		$6K Sell
3,273
-34,402
-91% -$79.7K ﹤0.01% 6581
2023
Q2 		$96K Sell
37,675
-34,870
-48% -$111K ﹤0.01% 5372
2023
Q1 		$291K Buy
+72,545
New +$145K ﹤0.01% 4322
2022
Q4 		– Sell
-192
Closed – – 7614
2022
Q3 		$0 Buy
+192
New +$502 ﹤0.01% 7769
2022
Q2 		– Sell
-653
Closed -$3K – 7649
2022
Q1 		$3K Sell
653
-1,483
-69% -$10.8K ﹤0.01% 7395
2021
Q4 		$23K Buy
+2,136
New +$24.5K ﹤0.01% 6741

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's PYXS Position: Q1 2026 in Review

Royal Bank of Canada reduced its Pyxis Oncology (PYXS) stake by 89% in Q1 2026, selling an estimated $74.9K and leaving 5,839 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #6220.

Royal Bank of Canada first reported a position in PYXS in Q4 2021 and has held it in 16 quarters since. The position peaked at $291K in Q1 2023. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Royal Bank of Canada held 5,839 shares of Pyxis Oncology worth $9K as of Q1 2026.
  • Royal Bank of Canada sold 49,712 Pyxis Oncology shares in Q1 2026, an estimated $74.9K.
  • Pyxis Oncology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6220 holding.
  • Royal Bank of Canada first reported a position in Pyxis Oncology in Q4 2021 and has held it in 16 quarters since.
  • Royal Bank of Canada's Pyxis Oncology position peaked at $291K in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.